Molecular Profile Detail

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile	Indication/Tumor Type	Response Type	Relevant Treatment Approaches	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
KMT2A rearrange FLT3 exon 14 ins	acute myeloid leukemia	sensitive		Revumenib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Revuforj (revumenib) reduced the leukemia burden and improved survival in an acute myeloid leukemia cell line xenograft model harboring a KMT2A rearrangement (MLL-r) and FLT3-ITD compared to vehicle-treated, but only inhibited cell viability after prolonged treatment in culture (PMID: 35017466).	35017466
KMT2A rearrange FLT3 exon 14 ins	acute myeloid leukemia	sensitive		Revumenib + Venetoclax	Preclinical - Cell line xenograft	Actionable	In a preclinical study, the combination of Revuforj (revumenib) and Venclexta (venetoclax) reduced the leukemia burden and improved survival in an acute myeloid leukemia cell line xenograft model harboring a KMT2A rearrangement and FLT3-ITD compared to either treatment alone, and demonstrated synergy in culture, resulting in decreased viability (PMID: 35017466).	35017466

Profile Name	KMT2A rearrange FLT3 exon 14 ins
Gene Variant Detail	FLT3 exon 14 ins (gain of function - predicted) KMT2A rearrange (unknown)
Relevant Treatment Approaches